普拉格雷与替格瑞洛在心肌梗死PCI患者中的比较
经多变量调整、IPTW和PSM分析,1年MACCE风险无显著差异(调整HR 1.03,95%CI 0.86-1.24),出血风险亦无显著差异(2.5% vs 3.2%,调整HR 0.92,95%CI 0.69-1.22)。
要点
- 普拉格雷与替格瑞洛在1年MACCE风险上无显著差异。
- 两药在死亡、再发心梗或卒中单独风险上无显著差异。
- 两药出血风险无显著差异(2.5% vs 3.2%)。
核心结论
- 在心肌梗死接受PCI的患者中,普拉格雷与替格瑞洛在1年随访期间疗效和安全性相似。
研究设计与样本
- 采用多变量调整、逆概率治疗加权(IPTW)和倾向评分匹配(PSM)调整混杂因素。
主要发现
- 普拉格雷组患者较年轻,更多为ST段抬高型心肌梗死,且更常合并糖尿病。
- 出院后6至12个月,每组约20%的患者停用出院时处方的P2Y12受体抑制剂。
- MACCE风险在普拉格雷组与替格瑞洛组间无显著差异(调整HR 1.03,95%CI 0.86-1.24)。
- 死亡、再发心肌梗死或卒中单独风险在两组间无显著差异。
- 出血风险在普拉格雷组与替格瑞洛组间无显著差异(2.5% vs 3.2%,调整HR 0.92,95%CI 0.69-1.22)。
临床怎么用
- 对于心肌梗死接受PCI的患者,选择普拉格雷或替格瑞洛均可,两者1年疗效和安全性相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The comparative efficacy and safety of prasugrel and ticagrelor in patients with myocardial infarction (MI) treated with percutaneous coronary intervention (PCI) remain unclear. We aimed to investigate the association of treatment with clinical outcomes. METHODS: In the SWEDEHEART (Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies) registry, all patients with MI treated with PCI and discharged on prasugrel or ticagrelor from 2010 to 2016 were included. Outcomes were 1-year major adverse cardiac and cerebrovascular events (MACCE, death, MI or stroke), individual components and bleeding. Multivariable adjustment, inverse probability of treatment weighting (IPTW) and propensity score matching (PSM) were used to adjust for confounders. RESULTS: We included 37 990 patients, 2073 in the prasugrel group and 35 917 in the ticagrelor group. Patients in the prasugrel group were younger, more often admitted with ST elevation MI and more likely to have diabetes. Six to twelve months after discharge, 20% of patients in each group discontinued the P2Y12 receptor inhibitor they received at discharge. The risk for MACCE did not significantly differ between prasugrel-treated and ticagrelor-treated patients (adjusted HR 1.03, 95% CI 0.86 to 1.24). We found no significant difference in the adjusted risk for death, recurrent MI or stroke alone between the two treatments. There was no significant difference in the risk for bleeding with prasugrel versus ticagrelor (2.5% vs 3.2%, adjusted HR 0.92, 95% CI 0.69 to 1.22). IPTW and PSM analyses confirmed the results. CONCLUSION: In patients with MI treated with PCI, prasugrel and ticagrelor were associated with similar efficacy and safety during 1-year follow-up.
引用
- Venetsanos D, Träff E, Erlinge D, et al. Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention. Heart. 2021. PMID: 33712510. doi:10.1136/heartjnl-2020-318694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。